GlassScriptPhysician profile
Rubylyn Rose Hilario
NPI 1952862104
$18,273.12
in general payments reported to CMS, 2019-2025
48 companies · $4,669 in 2025
The $4,669 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,487 · 2022: $2,886 · 2023: $3,798 · 2024: $4,433 · 2025: $4,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $55.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,844.47 |
| Education | $55.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,799.45 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $2,156.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $2,048.87 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,399.14 | 2021-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $1,181.69 | 2021-2025 | Unithroid |
| Amgen INC. | $1,059.38 | 2021-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $878.40 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $846.17 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $699.98 | 2021-2024 | |
| Ibsa Pharma INC. | $514.20 | 2021-2025 | Tirosint, Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $473.90 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $400.38 | 2023-2025 | Strensiq |
| Mannkind Corporation | $366.04 | 2021-2024 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $286.18 | 2021-2022 | |
| Abbott Laboratories | $245.50 | 2023-2025 | Freestyle Libre 3 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.22 | 2021-2025 | |
| Medtronic, INC. | $201.98 | 2021-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $200.54 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $195.69 | 2025 | Isturisa |
| Esperion Therapeutics, INC. | $193.91 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $173.51 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $165.83 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $156.09 | 2025 | Yorvipath |
| Radius Health, INC. | $121.38 | 2025 | Tymlos |
| Neurocrine Biosciences, INC. | $119.32 | 2025 | |
| Antares Pharma, INC. | $109.56 | 2024-2025 | Xyosted |
| Astellas Pharma US INC | $104.49 | 2024-2025 | Veozah |
| Amphastar Pharmaceuticals, INC. | $96.53 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $87.45 | 2025 | Tlando |
| Beta Bionics, INC. | $83.90 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascensia Diabetes Care US INC. | $83.78 | 2024-2025 | |
| Embecta Corp. | $69.49 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Regeneron Healthcare Solutions, INC. | $68.45 | 2023-2024 | Evkeeza, Praluent |
| Opko Pharmaceuticals, LLC | $45.33 | 2021-2022 | |
| Amarin Pharma, INC. | $45.27 | 2021 | |
| Lifescan, INC. | $44.94 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $42.74 | 2022 | |
| Halozyme INC | $42.29 | 2023 | |
| Acella Pharmaceuticals, LLC | $41.37 | 2025 | NP Thyroid 60 |
| Vivus LLC | $37.92 | 2021-2022 | |
| Insulet Corporation | $35.64 | 2023 | Omnipod |
| Madrigal Pharmaceuticals | $27.24 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $20.37 | 2021 | |
| Tolmar, INC. | $20.22 | 2025 | Jatenzo |
| Rhythm Pharmaceuticals, INC. | $19.97 | 2025 | Imcivree |
| Becton, Dickinson and Company | $18.94 | 2022 | |
| Glaxosmithkline, LLC. | $16.20 | 2025 | Arexvy, Shingrix |
| Clarus Therapeutics INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubylyn Hilario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.